Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives Average Recommendation of "Hold" from Analysts theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Enanta Pharmaceuticals (NASDAQ:ENTA) Upgraded at StockNews.com kopsource.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from kopsource.com Daily Mail and Mail on Sunday newspapers.
Tang Capital Management LLC raised its holdings in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Rating) by 45.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 200,000 shares of the biotechnology company’s stock after purchasing an additional 62,300 shares during the […]
Enanta Pharmaceuticals (NASDAQ:ENTA – Get Rating) had its price objective reduced by HC Wainwright from $68.00 to $48.00 in a research note issued to investors on Tuesday morning, The Fly reports. HC Wainwright also issued estimates for Enanta Pharmaceuticals’ Q3 2023 earnings at ($1.86) EPS, Q4 2023 earnings at ($2.56) EPS, FY2023 earnings at ($7.62) […]
Enanta Pharmaceuticals (NASDAQ:ENTA – Get Rating) had its target price trimmed by HC Wainwright from $68.00 to $48.00 in a research note issued to investors on Tuesday, The Fly reports. HC Wainwright also issued estimates for Enanta Pharmaceuticals’ Q3 2023 earnings at ($1.86) EPS, Q4 2023 earnings at ($2.56) EPS, FY2023 earnings at ($7.62) EPS, […]